Isoformselective inhibitors targeting Grp94 might be more effective for the cancers with high demand for proteins folding (multiple myeloma), inflammatory process (inflammatory colon carcinomas) and chronic infection (hepatocellular carcinoma) [127]. This evidence concerns the gene HSP90B1 and cancer.